Publicaciones en colaboración con investigadores/as de Pitié-Salpêtrière Hospital (14)

2023

  1. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    Neuro-oncology, Vol. 25, Núm. 1, pp. 37-53

2016

  1. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

    Cancer Investigation, Vol. 34, Núm. 1, pp. 39-44

2015

  1. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

    Journal of Neuro-Oncology, Vol. 121, Núm. 3, pp. 499-504

2014

  1. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool

    Neuro-Oncology, Vol. 16, Núm. 4, pp. 520-527

  2. An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas

    BioMed Research International, Vol. 2014

  3. Brain metastases

    Handbook of Clinical Neurology (Elsevier B.V.), pp. 1143-1157

  4. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

    Cancer, Vol. 120, Núm. 24, pp. 3972-3980

  5. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

  6. Management of elderly patients with gliomas

    Oncologist, Vol. 19, Núm. 12, pp. 1258-1267

2012

  1. Detection of IDH1 mutation in the plasma of patients with glioma

    Neurology, Vol. 79, Núm. 16, pp. 1693-1698

  2. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia

    Journal of Neuro-Oncology

2011

  1. Erratum to: Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia (Journal of Neuro-Oncology DOI: 10.1007/s11060-011-0752- 9)

    Journal of Neuro-Oncology

  2. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial

    Journal of Clinical Oncology, Vol. 29, Núm. 22, pp. 3050-3055

2006

  1. A novel dendritic cell subset involved in tumor immunosurveillance

    Nature Medicine, Vol. 12, Núm. 2, pp. 214-219